Drug Profile
Research programme: telomerase inhibitors - sanofi-aventis
Latest Information Update: 05 Dec 2007
Price :
$50
*
At a glance
- Originator CNRS; INSERM; sanofi-aventis
- Class Small molecules
- Mechanism of Action Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 04 Jul 2002 Preclinical trials in Cancer in France (unspecified route)